Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Capital Expenditures: 2018-2024

Historic Capital Expenditures for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to $211,000.

  • Silence Therapeutics' Capital Expenditures fell 95.31% to $3,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $59,000, marking a year-over-year decrease of 60.40%. This contributed to the annual value of $211,000 for FY2024, which is 276.79% up from last year.
  • Silence Therapeutics' Capital Expenditures amounted to $211,000 in FY2024, which was up 276.79% from $56,000 recorded in FY2023.
  • Silence Therapeutics' Capital Expenditures' 5-year high stood at $1.8 million during FY2021, with a 5-year trough of $56,000 in FY2023.
  • Over the past 3 years, Silence Therapeutics' median Capital Expenditures value was $173,000 (recorded in 2022), while the average stood at $146,667.
  • In the last 5 years, Silence Therapeutics' Capital Expenditures skyrocketed by 5,610.27% in 2020 and then plummeted by 90.41% in 2022.
  • Silence Therapeutics' Capital Expenditures (MRY) stood at $656,199 in 2020, then surged by 174.88% to $1.8 million in 2021, then plummeted by 90.41% to $173,000 in 2022, then crashed by 67.63% to $56,000 in 2023, then skyrocketed by 276.79% to $211,000 in 2024.
  • Its Capital Expenditures was $211,000 in FY2024, compared to $56,000 in FY2023 and $173,000 in FY2022.